ZNRF3 Inhibitors

The chemical class of ZNRF3 inhibitors consists of compounds that indirectly modulate the function of ZNRF3 by targeting the Wnt/β-catenin signaling pathway. These inhibitors act on different components of the Wnt signaling pathway, thereby influencing the regulatory role of ZNRF3, which is involved in controlling the levels of Wnt receptors on cell surfaces.

Compounds such as ICG-001, XAV-939, JW55, FH535, PKF118-310, CGP049090, KY1220, and PRI-724 are known for their inhibitory effects on Wnt/β-catenin signaling. By targeting this pathway, these compounds might indirectly impact ZNRF3's activity. For instance, ICG-001 and JW55 inhibit the interaction of β-catenin with TCF, and XAV-939 inhibits tankyrase, leading to the stabilization of Axin-a key component of the β-catenin destruction complex. The inhibition of these steps in the Wnt signaling pathway could influence the role of ZNRF3 in regulating Wnt receptor levels. Furthermore, compounds like Wnt-C59, LGK974, Salinomycin, and Pyrvinium pamoate also target various aspects of Wnt signaling. Wnt-C59 and LGK974 inhibit Wnt ligand production and secretion, respectively, thereby affecting the pathway where ZNRF3 functions. Salinomycin and Pyrvinium pamoate, known for their effects on Wnt/β-catenin signaling, could indirectly modulate the activity of ZNRF3.